CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 178 filers reported holding CRISPR THERAPEUTICS AG in Q1 2019. The put-call ratio across all filers is 1.73 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $24,175,200 | -20.8% | 447,606 | 0.0% | 0.06% | -18.6% |
| Q1 2024 | $30,508,825 | -4.1% | 447,606 | -11.9% | 0.07% | -11.4% |
| Q4 2023 | $31,807,060 | +37.9% | 508,100 | 0.0% | 0.08% | +29.5% |
| Q3 2023 | $23,062,659 | -19.3% | 508,100 | -0.1% | 0.06% | -14.1% |
| Q2 2023 | $28,561,674 | +24.1% | 508,758 | 0.0% | 0.07% | +22.4% |
| Q1 2023 | $23,011,124 | +11.3% | 508,758 | 0.0% | 0.06% | +1.8% |
| Q4 2022 | $20,681,013 | -37.8% | 508,758 | 0.0% | 0.06% | -41.2% |
| Q3 2022 | $33,247,000 | -5.8% | 508,758 | -12.4% | 0.10% | +1.0% |
| Q2 2022 | $35,302,000 | -3.2% | 580,918 | 0.0% | 0.10% | +17.1% |
| Q1 2022 | $36,464,000 | -17.2% | 580,918 | 0.0% | 0.08% | 0.0% |
| Q4 2021 | $44,022,000 | -32.3% | 580,918 | 0.0% | 0.08% | -33.9% |
| Q3 2021 | $65,022,000 | -30.9% | 580,918 | 0.0% | 0.12% | -29.1% |
| Q2 2021 | $94,045,000 | +31.5% | 580,918 | -1.0% | 0.18% | +25.9% |
| Q1 2021 | $71,504,000 | -26.7% | 586,818 | -7.9% | 0.14% | -30.2% |
| Q4 2020 | $97,546,000 | +51.8% | 637,100 | -17.1% | 0.20% | +31.8% |
| Q3 2020 | $64,256,000 | -18.9% | 768,250 | -28.7% | 0.15% | -23.0% |
| Q2 2020 | $79,222,000 | +73.3% | 1,078,000 | 0.0% | 0.20% | +46.3% |
| Q1 2020 | $45,718,000 | -40.5% | 1,078,000 | -14.6% | 0.13% | -21.6% |
| Q4 2019 | $76,844,000 | +117.6% | 1,261,700 | +46.4% | 0.17% | +96.6% |
| Q3 2019 | $35,320,000 | -9.8% | 861,663 | +3.6% | 0.09% | -8.4% |
| Q2 2019 | $39,171,000 | +43.5% | 831,663 | +8.8% | 0.10% | +39.7% |
| Q1 2019 | $27,299,000 | +25.0% | 764,263 | 0.0% | 0.07% | +13.3% |
| Q4 2018 | $21,835,000 | -35.6% | 764,263 | 0.0% | 0.06% | -24.1% |
| Q3 2018 | $33,895,000 | -8.6% | 764,263 | +21.0% | 0.08% | -27.5% |
| Q2 2018 | $37,101,000 | – | 631,400 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |